Fibroblast growth factor 23 and klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism

Annual Review of Physiology

Volumn 75, Issue , 2013, Pages 503-533

  Hu, Ming Chang ^a,b   Shiizaki, Kazuhiro ^a   Kuro O, Makoto ^a,b   Moe, Orson W ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bone; Calcium; FGF23; Kidney; Klotho; Phosphate

Indexed keywords

ADAM10 ENDOPEPTIDASE; BETA SECRETASE 1; CALCIMIMETIC AGENT; CALCIUM PHOSPHATE; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR 9; KERATINOCYTE GROWTH FACTOR; KLOTHO PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCALCIN; PARATHYROID HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; VANILLOID RECEPTOR 5; VITAMIN D;

AGING; CALCIUM HOMEOSTASIS; CALORIC INTAKE; CHRONIC KIDNEY DISEASE; ENERGY EXPENDITURE; GAS EXCHANGE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPARATHYROIDISM; INSULIN RELEASE; MINERAL DEFICIENCY; MINERAL METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; TANDEM REPEAT;

ANIMALS; BONE AND BONES; ENDOCRINE SYSTEM; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HOMEOSTASIS; HUMANS; INTESTINES; KIDNEY; MINERALS;

EID: 84873658813     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-030212-183727     Document Type: Review

References (186)

1. Lowenstam HA. 1981. Minerals formed by organisms. Science 211:1126-31
2. Berrill NJ. 1955. Origin of Vertebrates. Oxford: Clarendon
3. Haltstead LB. 1974. Vertebrate Hard Tissues. London: Wykeham
4. Pautard FG. 1961. Calcium, phosphorus and the origin of backbones. New Sci. 260:364
5. Ruben JA, Bennett AA. 1987. The evolution of bone. Evolution 41:1187-97
6. Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, et al. 2011. Leptin in human physiology and pathophysiology. Am. J. Physiol. Endocrinol. Metab. 301:E567-84
7. Ducy P. 2011. The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism. Diabetologia 54:1291-97
8. Karsenty G, Ferron M. 2012. The contribution of bone to whole-organism physiology. Nature 481:314-20
9. Eswarakumar VP, Lax I, Schlessinger J. 2005. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16:139-49
10. Mohammadi M, Olsen SK, Ibrahimi OA. 2005. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16:107-37
11. Itoh N, Ornitz DM. 2008. Functional evolutionary history of the mouse Fgf gene family. Dev. Dyn. 237:18-27
12. Beenken A, Mohammadi M. 2012. The structural biology of the FGF19 subfamily. Adv. Exp. Med. Biol. 728:1-24
13. Jones SA. 2012. Physiology of FGF15/19. Adv. Exp. Med. Biol. 728:171-82
14. Kuro-o M. 2012. Endocrine FGFs and Klothos. Austin, TX/New York: Landes Biosci./Springer. 233 pp.
15. Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, et al. 2010. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 24:2050-64
16. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, et al. 2007. Molecular insights into the Klotho-dependent, endocrine mode of action of FGF19 subfamily members. Mol. Cell. Biol. 27:3417-28
17. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, et al. 2010. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc. Natl. Acad. Sci. USA 107:407-12
18. White KE, Evans WE, O'Riordan JLH, Speer MC, Econs MJ, et al. 2000. Autosomal dominant hy-pophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26:345-48
19. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, et al. 2001. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. USA 98:6500-5
20. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. 2001. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 60:2079-86
21. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, et al. 2004. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Investig. 113:561-68
22. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, et al. 1997. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51
23. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, et al. 2006. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 281:6120-23
24. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, et al. 2011. FGF23 induces left ventricular hypertrophy. J. Clin. Investig. 121:4393-408
25. Kawaguchi H, Manabe N, Miyaura C, Chikuda H, Nakamura K, Kuro-o M. 1999. Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J. Clin. Investig. 104:229-37
26. Suga T, Kurabayashi M, Sando Y, Ohyama Y, Maeno T, et al. 2000. Disruption of the klotho gene causes pulmonary emphysema in mice. Defect in maintenance of pulmonary integrity during postnatal life. Am. J. Respir. Cell Mol. Biol. 22:26-33
27. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, et al. 2006. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-74
28. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, et al. 2010. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 24:3438-50
29. Murer H, Hernando N, Forster I, Biber J. 2003. Regulation of Na/Pi transporter in the proximal tubule. Annu. Rev. Physiol. 65:531-42
30. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, et al. 2006. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17:1305-15
31. Dusso AS, Brown AJ, Slatopolsky E. 2005. Vitamin D. Am. J. Physiol. Ren. Physiol. 289:F8-28
32. Farrow EG, Davis SI, Summers LJ, White KE. 2009. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J. Am. Soc. Nephrol. 20:955-60
33. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, et al. 2007. The parathyroid is a target organ for FGF23 in rats. J. Clin. Investig. 117:4003-8
34. Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, et al. 2007. Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells. J. Endocrinol. 195:125-31
35. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, et al. 2005. Suppression of aging in mice by the hormone Klotho. Science 309:1829-33
36. Ito S, Kinoshita S, Shiraishi N, Nakagawa S, Sekine S, et al. 2000. Molecular cloning and expression analyses of mouse βklotho, which encodes a novel Klotho family protein. Mech. Dev. 98:115-19
37. Ito S, Fujimori T, Hayashizaki Y, Nabeshima Y. 2002. Identification of a novel mouse membrane-bound family 1 glycosidase-like protein, which carries an atypical active site structure. Biochim. Biophys. Acta 1576:341-45
38. Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, et al. 2005. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146:4647-56
39. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, et al. 2007. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282:26687-95
40. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, et al. 2007. βKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. USA 104:7432-37
41. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, et al. 2005. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2:217-25
42. Ito S, Fujimori T, Furuya A, Satoh J, Nabeshima Y, Nabeshima Y. 2005. Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho. J. Clin. Investig. 115:2202-8
43. Yu C, Wang F, Kan M, Jin C, Jones RB, et al. 2000. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 275:15482-89
44. Choi M, Moschetta A, Bookout AL, Peng L, Umetani M, et al. 2006. Identification of a hormonal basis for gallbladder filling. Nat. Med. 12:1253-55
45. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, et al. 2011. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331:1621-24
46. Tomlinson E, Fu L, John L, Hultgren B, Huang X, et al. 2002. Transgenic mice expressing human fibro-blast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143:1741-47
47. Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, et al. 2011. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1αpathway. Cell Metab. 13:729-38
48. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. 2012. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 26:312-24
49. Kliewer SA, Mangelsdorf DJ. 2010. Fibroblast growth factor 21: from pharmacology to physiology. Am. J. Clin. Nutr. 91:254S-57S
50. Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, et al. 2009. FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. USA 106:10853-58
51. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, et al. 2007. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab. 5:415-25
52. Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, et al. 2011. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 152:2996-3004
53. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, et al. 2012. FGF21 regulates PGC-1cx and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26:271-81
54. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. 2007. Hepatic fibroblast growth factor 21 is regulated by PPARtx and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5:426-37
55. Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y. 1998. Identification of the human klotho gene and its two transcripts encoding membrane and secreted Klotho protein. Biochem. Biophys. Res. Commun. 242:626-30
56. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, et al. 2004. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 565:143-47
57. Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR. 2007. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc. Natl. Acad. Sci. USA 104:19796-801
58. Bloch L, Sineshchekova O, Reichenbach D, Reiss K, Saftig P, et al. 2009. Klotho is a substrate for ex-, β3-and y-secretase. FEBS Lett. 583:3221-24
59. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, et al. 2011. Klotho deficiency causes vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 22:124-36
60. Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-o M, Huang CL. 2008. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc. Natl. Acad. Sci. USA 105:9805-10
61. Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG. 2005. The β3-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 310:490-93
62. Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, et al. 2007. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 317:803-6
63. Doi S, Zou Y, Togao O, Pastor JV, John GB, et al. 2011. Klotho inhibits transforming growth factor-131 (TGF-131) signaling and suppresses renal fibrosis and cancer metastasis in mice. J. Biol. Chem. 286:8655-65
64. + excretion by Klotho. Mol. Pharmacol. 76:38-46
65. Tohyama O, Imura A, Iwano A, Freund JN, Henrissat B, et al. 2004. Klotho is a novel β3-glucuronidase capable of hydrolyzing steroid β3-glucuronides. J. Biol. Chem. 279:9777-84
66. Lopez I, Rodriguez-Ortiz ME, Almaden Y, Guerrero F, de Oca AM, et al. 2011. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 80:475-82
67. Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR, Martinez-Moreno JM, Ramirez AP, et al. 2012. Calcium deficiency reduces circulating levels of FGF23. J. Am. Soc. Nephrol. 23:1190-97
68. Rhee Y, Bivi N, Farrow E, Lezcano V, Plotkin LI, et al. 2011. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49:636-43
69. Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, et al. 2006. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J. Clin. Investig. 116:3150-59
70. Haussler MR, Whitfield GK, Kaneko I, Forster R, Saini R, et al. 2011. The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev. Endocr. Metab. Disord. 13:57-69
71. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, et al. 2002. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87:4957-60
72. Weber TJ, Liu S, Indridason OS, Quarles LD. 2003. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner. Res. 18:1227-34
73. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, et al. 2003. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 348:1656-63
74. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, et al. 2006. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 38:1310-15
75. Wohrle S, Bonny O, Beluch N, Gaulis S, Stamm C, et al. 2011. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J. Bone Miner. Res. 26:2486-97
76. Martin A, Liu S, David V, Li H, Karydis A, et al. 2011. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J. 25:2551-62
77. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. 2010. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am. J. Physiol. Ren. Physiol. 299:F882-89
78. Berndt T, Kumar R. 2007. Phosphatonins and the regulation of phosphate homeostasis. Annu. Rev. Physiol. 69:341-59
79. Yuan Q, Sato T, Densmore M, Saito H, Schuler C, et al. 2011. FGF-23/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH. J. Bone Miner. Res. 26:2026-35
80. Barthel TK, Mathern DR, Whitfield GK, Haussler CA, Hopper HA 4th, et al. 2007. 1, 25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J. Steroid Biochem. Mol. Biol. 103:381-88
81. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE. 2005. Genetic dissection of phosphate-and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36:971-77
82. Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, et al. 2007. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J. Bone Miner. Metab. 25:419-22
83. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. 2006. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Res. 21:1187-96
84. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, et al. 2007. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J. Clin. Investig. 117:2684-91
85. Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, et al. 2012. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin. Exp. Nephrol. 16:722-29
86. Pavik I, Jaeger P, Ebner L, Poster D, Krauer F, et al. 2012. Soluble klotho and autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 7:248-57
87. Hu MC, Kuro-o M, Moe OW. 2012. Secreted klotho and chronic kidney disease. Adv. Exp. Med. Biol. 728:126-57
88. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, et al. 2001. Severely reduced production of klotho in human chronic renal failure kidney. Biochem. Biophys. Res. Commun. 280:1015-20
89. Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, et al. 2009. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J. 23:433-41
90. Bai X, Dinghong Q, Miao D, Goltzman D, Karaplis AC. 2009. Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype. Am. J. Physiol. Endocrinol. Metab. 296:E79-88
91. Nakatani T, Ohnishi M, Razzaque MS. 2009. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophos-phatemic (Hyp) mouse model. FASEB J. 23:3702-11
92. Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, et al. 2010. Circulating levelsofsoluble Klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J. Clin. Endocrinol. Metab. 95:E352-57
93. Marsell R, Krajisnik T, Goransson H, Ohlsson C, Ljunggren O, et al. 2008. Gene expression analysis of kidneys from transgenic mice expressingfibroblast growth factor-23. Nephrol. Dial. Transplant. 23:827-33
94. Takeshita K, Fujimori T, Kurotaki Y, Honjo H, Tsujikawa H, et al. 2004. Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation 109:1776-82
95. Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, et al. 2010. FGF23 fails to inhibit uremic parathyroid glands. J. Am. Soc. Nephrol. 21:1125-35
96. Tatsumi S, Segawa H, Morita K, Haga H, Kouda T, et al. 1998. Molecular cloning and hormonal regulation of PiT-1, a sodium-dependent phosphate cotransporter from rat parathyroid glands. Endocrinology 139:1692-99
97. Nabeshima Y. 2008. The discovery of α-Klotho and FGF23 unveiled new insight into calcium and phosphate homeostasis. Cell. Mol. Life Sci. 65:3218-30
98. Yoshida T, Fujimori T, Nabeshima Y. 2002. Mediation of unusually high concentrations of 1, 25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1α-hydroxylase gene. Endocrinology 143:683-89
99. Carpinelli MR, Wise AK, Burt RA. 2011. Vitamin D-deficient diet rescues hearing loss in Klotho mice. Hear. Res. 275:105-9
100. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. 2003. Klotho, agene related toasyndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol. Endocrinol. 17:2393-403
101. Forster RE, Jurutka PW, Hsieh JC, Haussler CA, Lowmiller CL, et al. 2011. Vitamin D receptor controls expression of the anti-aging klotho gene in mouse and human renal cells. Biochem. Biophys. Res. Commun. 414:557-62
102. Mackay EM, Oliver J. 1935. Renal damage following the ingestion of a diet containing an excess of inorganic phosphate. J. Exp. Med. 61:319-34
103. Haut LL, Alfrey AC, Guggenheim S, Buddington B, Schrier N. 1980. Renal toxicity of phosphate in rats. Kidney Int. 17:722-31
104. Ori Y, Herman M, Tobar A, Chernin G, Gafter U, et al. 2008. Acute phosphate nephropathy-an emerging threat. Am. J. Med. Sci. 336:309-14
105. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. 2005. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112:2627-33
106. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. 2001. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodial-ysis patients. J. Am. Soc. Nephrol. 12:2131-38
107. Martin KJ, Gonzalez EA. 2011. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: What is normal, when to start, and how to treat? Clin. J. Am. Soc. Nephrol. 6:440-46
108. Hiza H, Bente L, Fungwe T. 2008. Nutrient content of the U. S. food supply, 2005. Home Econ. Res. Rep. No. 58, US Dep. Agric., Washington, DC
109. Uribarri J. 2009. Phosphorus additives in food and their effect in dialysis patients. Clin. J. Am. Soc. Nephrol. 4:1290-92
110. Uribarri J. 2007. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin. Dial. 20:295-301
111. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, et al. 2008. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 371:2173-82
112. Bell RR, Draper HH, Tzeng DY, Shin HK, Schmidt GR. 1977. Physiological responses of human adults to foods containing phosphate additives. J. Nutr. 107:42-50
113. Bertram JF, Douglas-Denton RN, Diouf B, Hughson MD, Hoy WE. 2011. Human nephron number: implications for health and disease. Pediatr. Nephrol. 26:1529-33
114. Tan JC, Busque S, Workeneh B, Ho B, Derby G, et al. 2010. Effects of aging on glomerular function and number in living kidney donors. Kidney Int. 78:686-92
115. Aihara K, Byer KJ, Khan SR. 2003. Calcium phosphate-induced renal epithelial injury and stone formation: involvement of reactive oxygen species. Kidney Int. 64:1283-91
116. Di Marco GS, Hausberg M, Hillebrand U, Rustemeyer P, Wittkowski W, et al. 2008. Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am. J. Physiol. Ren. Physiol. 294:F1381-87
117. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, et al. 2000. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 87:E10-17
118. Sage AP, Lu J, Tintut Y, Demer LL. 2011. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int. 79:414-22
119. Villa-Bellosta R, Sorribas V. 2009. Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calcium-phosphate deposition. Arterioscler. Thromb. Vasc. Biol. 29:761-66
120. Bank N, Su WS, Aynedjian HS. 1978. A micropuncture study of renal phosphate transport in rats with chronic renal failure and secondary hyperparathyroidism. J. Clin. Investig. 61:884-94
121. Khan SR. 2004. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin. Exp. Nephrol. 8:75-88
122. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, et al. 2007. Role of hyperphosphatemia and 1, 25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J. Am. Soc. Nephrol. 18:2116-24
123. Hesse M, Frohlich LF, Zeitz U, Lanske B, Erben RG. 2007. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol. 26:75-84
124. Razzaque MS, Sitara D, Taguchi T, St-Arnaud R, Lanske B. 2006. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J. 20:720-22
125. Ohnishi M, Nakatani T, Lanske B, Razzaque MS. 2009. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1α-hydroxylase. Kidney Int. 75:1166-72
126. Ohnishi M, Razzaque MS. 2010. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J. 24:3562-71
127. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. 2009. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 76(Suppl. 113):1-130
128. Moorthi RN, Moe SM. 2011. CKD-mineral and bone disorder: core curriculum 2011. Am. J. Kidney Dis. 58:1022-36
129. Chmielewski M, Carrero JJ, Stenvinkel P, Lindholm B. 2009. Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. Curr. Opin. Lipidol. 20:3-9
130. Hruska KA, Choi ET, Memon I, Davis TK, Mathew S. 2010. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr. Nephrol. 25:769-78
131. Coresh J, Astor B, Sarnak MJ. 2004. Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 13:73-81
132. Kendrick J, Chonchol MB. 2008. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat. Clin. Pract. Nephrol. 4:672-81
133. Moe SM, Chen NX. 2008. Mechanisms of vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 19:213-16
134. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B. 2006. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J. Am. Soc. Nephrol. 17:S267-73
135. Mizobuchi M, Towler D, Slatopolsky E. 2009. Vascular calcification: the killer of patients with chronic kidney disease. J. Am. Soc. Nephrol. 20:1453-64
136. De Schutter TM, Neven E, Persy VP, Behets GJ, Postnov AA, et al. 2011. Vascular calcification is associated with cortical bone loss in chronic renal failure rats with and without ovariectomy: the calcification paradox. Am. J. Nephrol. 34:356-66
137. Hu MC, Kuro-o M, Moe OW. 2010. Klotho and kidney disease. J. Nephrol. 23(Suppl. 16):136-44
138. Haruna Y, Kashihara N, Satoh M, Tomita N, Namikoshi T, et al. 2007. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc. Natl. Acad. Sci. USA 104:2331-36
139. Zhao Y, Banerjee S, Dey N, Le Jeune WS, Sarkar PS, et al. 2011. Klotho depletion contributestoincreased inflammation in kidney of the db/db mouse model of diabetes via RelA (serine)536 phosphorylation. Diabetes 60:1907-16
140. Wang Y, Sun Z. 2009. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension 54:810-17
141. Aizawa H, Saito Y, Nakamura T, Inoue M, Imanari T, et al. 1998. Downregulation of the Klotho gene in the kidney under sustained circulatory stress in rats. Biochem. Biophys. Res. Commun. 249:865-71
142. Asai O, Nakatani K, Tanaka T, Sakan H, Imura A, et al. 2012. Decreased renal α-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion. Kidney Int. 81:539-47
143. Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, et al. 2010. Establishment of sandwich ELISA for soluble α-Klotho measurement: age-dependent change of soluble α-Klotho levels in healthy subjects. Biochem. Biophys. Res. Commun. 398:513-18
144. Sugiura H, Tsuchiya K, Nitta K. 2011. Circulating levels of soluble α-Klotho in patients with chronic kidney disease. Clin. Exp. Nephrol. 15:795-96
145. Krajisnik T, Olauson H, Mirza MA, Hellman P, Akerstrom G, et al. 2010. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int. 78:1024-32
146. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, et al. 2005. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16:2205-15
147. Kobayashi K, Imanishi Y, Miyauchi A, Onoda N, Kawata T, et al. 2006. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur. J. Endocrinol. 154:93-99
148. Goldsmith DJ, Cunningham J. 2011. Mineral metabolism and vitamin D in chronic kidney disease-more questions than answers. Nat. Rev. Nephrol. 7:341-46
149. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. 2010. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 77:211-18
150. Drueke TB. 2010. Klotho, FGF23, and FGF receptors in chronic kidney disease: A yin-yang situation? Kidney Int. 78:1057-60
151. Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, et al. 2010. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J. Clin. Endocrinol. Metab. 95:578-85
152. Lafage-Proust MH. 2010. Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients? Kidney Int. 77:390-92
153. Saji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, et al. 2009. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron. Physiol. 111:59-66
154. Shiraki-Iida T, Iida A, Nabeshima Y, Anazawa H, Nishikawa S, et al. 2000. Improvement of multiple pathophysiological phenotypes of klotho (kl/kl) mice by adenovirus-mediated expression of the klotho gene. J. Gene Med. 2:233-42
155. Lau WL, Festing MH, Giachelli CM. 2010. Phosphate and vascular calcification: emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb. Haemost. 104:464-70
156. de Oliveira RM. 2006. Klotho RNAi induces premature senescence of human cells via a p53/p21 dependent pathway. FEBS Lett. 580:5753-58
157. Nakano-Kurimoto R, Ikeda K, Uraoka M, Nakagawa Y, Yutaka K, et al. 2009. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am. J. Physiol. Heart Circ. Physiol. 297:H1673-84
158. Lim K, Lu TS, Molostvov G, Lee C, Lam F, et al. 2012. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to FGF-23. Circulation 125:2243-55
159. Donate-Correa J, Mora-Fernandez C, Martinez-Sanz R, Muros-de-Fuentes M, Perez H, et al. 2011. Expression of FGF23/KLOTHO system in human vascular tissue. Int. J. Cardiol. In press; doi:10.1016/j.ijcard.2011.08.850
160. London GM, Marchais SJ, Guerin AP, Metivier F. 1989. Contributive factors to cardiovascular hypertrophy in renal failure. Am. J. Hypertens. 2:261S-3S
161. Burrell LM, Johnston CI. 1997. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Drugs Aging 10:421-34
162. Achinger SG, Ayus JC. 2005. The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int. Suppl. 67(Suppl. 95):37-42
163. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. 2009. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207:546-51
164. Carter JL, O'Riordan SE, Eaglestone GL, Delaney MP, Lamb EJ. 2008. Bone mineral metabolism and its relationship to kidney disease in a residential care home population: a cross-sectional study. Nephrol. Dial. Transplant. 23:3554-65
165. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, et al. 2010. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin. J. Am. Soc. Nephrol. 5:286-91
166. Fukagawa M, Kazama JJ. 2006. FGF23: its role in renal bone disease. Pediatr. Nephrol. 21:1802-6
167. Yamashita T, Nifuji A, Furuya K, Nabeshima Y, Noda M. 1998. Elongation of the epiphyseal trabecular bone in transgenic mice carrying a klotho gene locus mutation that leads to a syndrome resembling aging. J. Endocrinol. 159:1-8
168. Shalhoub V, Ward SC, Sun B, Stevens J, Renshaw L, et al. 2011. Fibroblast growth factor 23 (FGF23)and oc-klotho stimulate osteoblastic MC3T3. E1 cell proliferation and inhibit mineralization. Calcif. Tissue Int. 89:140-50
169. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, et al. 2009. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol. 20:388-96
170. Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD. 2011. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin. J. Am. Soc. Nephrol. 6:50-62
171. Wolf M, Betancourt J, Chang Y, Shah A, Teng M, et al. 2008. Impact of activated vitamin D and race on survival among hemodialysis patients. J. Am. Soc. Nephrol. 19:1379-88
172. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, et al. 2004. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 350:1516-25
173. Drueke TB, Ritz E. 2009. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin. J. Am. Soc. Nephrol. 4:234-41
174. Razzaque MS. 2010. Therapeutic potential of klotho-FGF23 fusion
175. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, et al. 2010. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 78:975-80
176. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, et al. 2012. FGF23 neutralization improves secondary hyperparathyroidism and osteodystrophy parameters yet exacerbates vascular calcification in chronic kidney disease rats. J. Clin. Investig. 122:2543-53
177. Hu MC, Shi M, Zhang J, Quinones H, Kuro-o M, Moe OW. 2010. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int. 78:1240-51
178. Doi S, Zou Y, Togao O, Pastor JV, John GB, et al. 2011. Klotho inhibits transforming growth factor-131 (TGF-β31) signaling and suppresses renal fibrosis and cancer metastasis in mice. J. Biol. Chem. 286:8655-65
179. Morishita K, Shirai A, Kubota M, Katakura Y, Nabeshima Y, et al. 2001. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J. Nutr. 131:3182-88
180. Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, et al. 2002. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 39:838-43
181. Zhang H, Li Y, Fan Y, Wu J, Zhao B, et al. 2008. Klotho is a target gene of PPAR-y. Kdney Int. 74:732-39
182. Itoh N, Ornitz DM. 2011. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem. 149:121-30
183. Choi M, Moschetta A, Bookout AL, Peng L, Umetani M, et al. 2006. Identification of a hormonal basis for gallbladder filling. Nat. Med. 12:1253-55
184. Yu J, Deng M, Zhao J, Huang L. 2010. Decreased expression of klotho gene in uremic atherosclerosis in apolipoprotein E-deficient mice. Biochem. Biophys. Res. Commun. 391:261-66
185. Zhou Q, Lin S, Tang R, Veeraragoo P, Peng W, Wu R. 2010. Role of fosinopril and valsartan on klotho gene expression induced by angiotensin II in rat renal tubular epithelial cells. Kidney Blood Press. Res. 33:186-92
186. Devaraj S, Syed B, Chien A, Jialal I. 2012. Validation of an immunoassay for soluble klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. Am. J. Clin. Pathol. 137:479-85